QIs assessing the care pathway in onco-hematology are very limited and often linked to hospital concerns. They do not take into account the entire pathway, and in particular the coordination links between non-hospital professionals (GPs, pharmacists and private nurses) and the hospital. Our objective is to select a set of QIs on the care pathway in onco-hematology by involving all relevant stakeholders: hospital professionals, patient associations and non-hospital professionals.
The study was conducted in 3 main stages. First, a review of available QIs assessing the clinical pathway was conducted from the gray literature and literature reviews. Selection criteria were applied to extract oncological clinical pathway QIs. Secondly, the list of pre-selected QIs was submitted separately to 3 working groups for a consensus selection: hospital professionals (oncologists, pharmacists and SRNs of various hospitals in France), patient associations and non-hospital professionals. The final stage consists of meeting all the experts to pool the selected QIs: a rating of each QI on two dimensions (relevance and feasibility) (1st meeting) and a vote for a final consensus (2nd meeting).
5731 QIs were identified and 131 selected after application of selection criteria to extract onco-hematology care pathway QIs. 36 QIs were selected by the 3 working groups, including 1 by all 3 groups (13 QIs by hospital professionals, 10 by patient associations and 13 by non-hospital professionals). Experts met by videoconference and established a score for the 34 QIs, the weighted averages range from 12.9 to 16.4.
Final consensus for a set of QIs will be achieved in July 2022 during a plenary meeting. The project will provide a consensus for set of QIs by involving all relevant stakeholders: hospital professionals, patient associations and non-hospital professional involved in the care pathway in onco-haematology. These QIs could then be tested in the institutions of the project participants in order to validate their metrological qualities.
Clinical trial identification
Legal entity responsible for the study
M. Ferrua: Financial Interests, Personal, Advisory Role: Novatis Oncology. All other authors have declared no conflicts of interest.